Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) CFO Marc Wilson sold 32,129 shares of the firm’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $43.61, for a total transaction of $1,401,145.69. Following the completion of the sale, the chief financial officer now directly owns 111,092 shares of the company’s stock, valued at $4,844,722.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Crinetics Pharmaceuticals Stock Performance
Shares of CRNX stock traded down $0.53 during trading hours on Tuesday, reaching $45.54. The company had a trading volume of 1,253,879 shares, compared to its average volume of 858,840. The firm has a market cap of $3.59 billion, a PE ratio of -12.12 and a beta of 0.68. The business has a fifty day moving average price of $46.41 and a 200-day moving average price of $42.12. Crinetics Pharmaceuticals, Inc. has a one year low of $15.76 and a one year high of $53.70.
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). The company had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.20 million. The company’s revenue was down 76.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.85) earnings per share. Equities research analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.53 EPS for the current year.
Hedge Funds Weigh In On Crinetics Pharmaceuticals
Wall Street Analysts Forecast Growth
Several research firms have recently commented on CRNX. Citigroup began coverage on shares of Crinetics Pharmaceuticals in a research report on Wednesday, March 6th. They issued a “buy” rating and a $68.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Crinetics Pharmaceuticals in a research note on Tuesday, May 14th. JMP Securities restated a “market outperform” rating and set a $80.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Tuesday, June 4th. Robert W. Baird raised their price objective on shares of Crinetics Pharmaceuticals from $52.00 to $62.00 and gave the company an “outperform” rating in a research note on Thursday, May 23rd. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Friday. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $62.50.
Read Our Latest Analysis on CRNX
Crinetics Pharmaceuticals Company Profile
Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
Recommended Stories
- Five stocks we like better than Crinetics Pharmaceuticals
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- RXO Shares Surge Following New Acquisition Deal
- What is the Hang Seng index?
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.